A recent trial had also discussed that SGLT-2 inhibitor, particularly empagliflozin, was associated with improvement in endothelial function measured with FMD in the population with CHF and type 2 diabetes [57]. The gene discussed is SLC5A2; the disease is congestive heart failure.